Soliton, Inc., (SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center (“MD Anderson”), today...
Personalized Stem Cells, Inc. announces clinical trial sites qualified for FDA approved clinical trial for treatment of osteoarthritis with stem cells. Personalized Stem Cells, Inc (“PSC”), a human adipose-derived stem cell company, has completed training and site...
Company to provide additional transport stability data points in response to FDA Clinical Hold Letter CMC clearance for VIITAL™ trial anticipated in Q4 2019 Investor conference call today, Monday, September 23 at 09:30 a.m. ET NEW YORK and CLEVELAND, Sept. 23, 2019...
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that its collaboration partner, Kissei Pharmaceuticals Co., Ltd. (“Kissei”), has initiated a Phase 3 trial in Japan of fostamatinib disodium hexahydrate in adult patients with chronic immune...
Email
Text